ALTERITY THERAPEUTICS LIMITED (ATH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ATH

ATH - ALTERITY THERAPEUTICS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.01
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.51

15 Jun
2026

0.015

OPEN

$0.51

3.03%

HIGH

$0.52

304,013

LOW

$0.47

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-9.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx23.2
Net Operating Cash Flow xxxxxxxxxxxxxxx-11.5 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-43.23 %
Return on Invested Capital xxxxxxxxxxxxxxx-43.12 %
Return on Assets xxxxxxxxxxxxxxx-37.23 %
Return on Equity xxxxxxxxxxxxxxx-43.23 %
Return on Total Capital xxxxxxxxxxxxxxx-70.82 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-11.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx41 M
Price To Book Value xxxxxxxxxxxxxxx2.15

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx20 M
Research & Development xxxxxxxxxxxxxxx14 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

10/06/2026

1

Speculative Buy

$0.95

86.27%

Canaccord Genuity maintains a Speculative Buy rating for Alterity Therapeutics with its target price increased to $0.95 following an update confirming regulatory alignment for a Phase III registrational trial.

The upcoming 200-patient study will evaluate lead candidate ATH434 at an optimal 50mg dose using a modified UMSARS Part I primary endpoint after securing formal FDA endorsement on all key design elements.

Commentary suggests patient selection and stratification pathways are uniquely de-risked through the integration of a quantitative neuroimaging atrophy index alongside validated cerebrospinal fluid biomarkers.

Phase II clinical datasets demonstrated a 48% slowing of disease progression, highlighting the asset's structural differentiation as an upstream modulator compared to alternative intracellular alpha-synuclein clearance strategies.

Execution of the clinical manufacturing scale-up keeps the program on track for a late 2026 trial commencement, positioned to act as a significant catalyst for global corporate partnering discussions, the report concludes.
Access Extra Coverage Research History >

ATH STOCK CHART

FNArena News on ATH

5
Class of 2020

Jul 09 2020 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL: Buy Trigger Ahead

Apr 26 2022 - Technicals
2
Why CSL Fell Sharply Yesterday

Dec 17 2021 - Australia
3
Beating The Biotech Blues

Sep 14 2021 - International
4
Uncertainty Prevails For CSL

Aug 19 2021 - Australia
5
Flying High – Medicinal Marijuana In Australia

Jul 26 2021 - Australia
6
Wesfarmers On Drugs?

Jul 13 2021 - Australia
7
Is CSL’s Plasma Recovery Now Priced In?

Jun 23 2021 - Australia
8
CSL: Buy The Dip

Jun 22 2021 - Technicals
9
CSL To Retest Its High?

May 25 2021 - Technicals
10
Treasure Chest: CSL Plasma At Turning Point?

May 05 2021 - Treasure Chest